Boston Oncology Arabia (BOA), a leading bio-generic drugs manufacturer in Saudi Arabia, has secured a USD 35 million investment from TVM Capital Healthcare (TVM). BOA, headquartered in Riyadh with a production facility in Sudair Industrial City, focuses on developing and manufacturing internationally licensed therapeutics crucial for critical conditions. This investment is expected to propel BOA into full formulation and fill and finish manufacturing, enhancing its role in Saudi Arabia’s Vision 2030 by strengthening local supply chains for critical care medicines. Abdullah Baaj, the founder and CEO of BOA, emphasized the value creation potential of BOA’s localization model in competitive markets, while Orhan Osmansoy, Managing Partner at TVM, highlighted the investment’s role in reducing healthcare costs and improving access to essential pharmaceuticals. Broadgate Advisers, represented by Habib Aoun, has been active in this advisory role since BOA’s early stages, noting the strong investor interest in Saudi Arabia’s healthcare sector.

Healthcare, Private Equity, Pharmaceuticals,Saudi Arabia, MENA